Bradley Burnam, founder and CEO of Turn Therapeutics, discussed GX-03's encouraging interim safety profile, regulatory strategy, and next steps in clinical development.
Bradley Burnam
Advertisement
Bradley Burnam is the founder and chief executive officer of Turn Therapeutics.
Articles by Bradley Burnam
Bradley Burnam, founder and CEO of Turn Therapeutics, explains the statistical rationale behind GX-03's phase 2 end point strategy and patient stratification.
Bradley Burnam, founder and CEO of Turn Therapeutics, discussed interim phase 2 trial findings showing GX-03 efficacy across a broader range of EASI severity scores in atopic dermatitis.
Case reports showed encouraging outcomes in eczema, but the company is pursuing deeper validation.
Bradley Burnam discusses results from an in-vivo model of atopic dermatitis.
Advertisement
Latest Updated Articles
Turn Therapeutics Pushes Eczema Therapy Into Clinical TrialsAugust 26th 2025
Advertisement
Advertisement
Trending on Dermatology Times
1
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
2
Social Media Mythbusters: The Summer Skin Care "Shutdown"
3
New Review Confirms How Nonmedicated Skin Care Vehicles Drive Clinical Improvement
4
Breakout Bulletin: July 13-July 17
5